Publications: Dr Louise Zolfaghari

Lane R, Mencel J, Turkes F, Challoner BR, McCafferty N, Ntellas P, Barber LJ, Rana I et al. ( 2024 ) . 124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial . Annals of Oncology vol. 35 ,

Challoner BR, Slater SC, Sansano HB, Aresu M, Bryant A, Chen H-C, Begum R, Rana T et al. ( 2024 ) . 30P Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC) . Annals of Oncology vol. 35 ,

Newey A, Yu L, Barber LJ, Choudhary JS, Bassani-Sternberg M, Gerlinger M ( 2023 ) . Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ . Cancer Research Communications vol. 3 , ( 11 ) 2345 - 2357 .

Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al. ( 2023 ) . Genetic and immune landscape evolution in MMR‐deficient colorectal cancer . The Journal of Pathology vol. 262 , ( 2 ) 226 - 239 .

Mencel J, Turkes F, Barber L, Challoner B, Buzzetti M, Tran A, Chen H, McCafferty N et al. ( 2023 ) . P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer . Annals of Oncology vol. 34 , s53 - s54 .

Gerlinger M, Gordon A, Barber LJ, Laliotis G, Athauda A, Challoner B, Woolston A, Mansukhani S et al. ( 2023 ) . Abstract 5591: Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma . Cancer Research vol. 83 , ( 7_Supplement ) 5591 - 5591 .

McCafferty N, Fong C, Barber LJ, Woolston A, Kleftogiannis D, Rana T, Cromarty S, Kidd S et al. ( 2023 ) . Abstract 5593: Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing . Cancer Research vol. 83 , ( 7_Supplement ) 5593 - 5593 .

Barber LJ, Ward TA, Hartley JA, McHugh PJ ( 2023 ) . DNA Interstrand Cross-Link Repair in the Saccharomyces cerevisiae Cell Cycle: Overlapping Roles for PSO2 (SNM1) with MutS Factors and EXO1 during S Phase . Molecular and Cellular Biology vol. 25 , ( 6 ) 2297 - 2309 .

Youds JL, Barber LJ, Ward JD, Collis SJ, O'Neil NJ, Boulton SJ, Rose AM ( 2023 ) . DOG-1 Is the Caenorhabditis elegans BRIP1/FANCJ Homologue and Functions in Interstrand Cross-Link Repair . Molecular and Cellular Biology vol. 28 , ( 5 ) 1470 - 1479 .

Lambert S, Mason SJ, Barber LJ, Hartley JA, Pearce JA, Carr AM, McHugh PJ ( 2023 ) . Schizosaccharomyces pombe Checkpoint Response to DNA Interstrand Cross-Links . Molecular and Cellular Biology vol. 23 , ( 13 ) 4728 - 4737 .

Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al. ( 2022 ) . Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer . Cancer Research . vol. 82 , a002 - a002 .

Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al. ( 2022 ) . Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer . Cancer Research . vol. 82 , pr012 - pr012 .

Woolston A, Barber LJ, Griffiths B, Pich O, Lopez-Bigas N, Matthews N, Rao S, Watkins D et al. ( 2021 ) . Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer . Nature Ecology & Evolution vol. 5 , ( 7 ) 1024 - 1032 .

Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, Griffiths B, Fenwick K, Bettoni F et al. ( 2020 ) . Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy . Cancers vol. 12 , ( 12 )

Khan K, Gonzalez-Exposito R, Cunningham D, Koh D-M, Woolston A, Barber L, Griffiths B, Kouvelakis K et al. ( 2020 ) . Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data . Frontiers in Oncology vol. 10 ,

Masotti C, Knebel FH, Linck RDM, Lima J, Shimada AK, Alessi JV, Zucchetti BM, Kleftogiannis D et al. ( 2020 ) . Abstract A19: Detection of ESR1 mutations in plasma cell-free DNA from metastatic ER-positive breast cancer patients resistant to hormone therapy . Clinical Cancer Research vol. 26 , ( 11_Supplement ) a19 - a19 .

Challoner BR, von Loga K, Woolston A, Griffiths B, Sivamanoharan N, Semiannikova M, Newey A, Barber LJ et al. ( 2020 ) . Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes . Journal of the National Cancer Institute vol. 113 , ( 1 ) 88 - 98 .

von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al. ( 2020 ) . Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer . Nature Communications vol. 11 , ( 1 )

von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al. ( 2020 ) . Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer . Nature Communications vol. 11 , ( 1 )

Masotti C, Knebel FH, Linck RDM, Lima J, Shimada AK, Alessi JV, Zucchetti BM, Kleftogiannis D et al. ( 2020 ) . Detection of ESR1 mutations in plasma cell-free DNA from metastatic ER-positive breast cancer patients resistant to hormone therapy . CLINICAL CANCER RESEARCH . vol. 26 , 43 - 44 .

Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G et al. ( 2019 ) . Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Davidson M, Mansukhani S, Starling N, Chau I, Watkins D, Cunningham D, Rao S, Lazaro-Alcausi R et al. ( 2019 ) . 674PD Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in . Annals of Oncology vol. 30 ,

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al. ( 2019 ) . Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer . Cancer Cell vol. 36 , ( 1 ) 35 - 50.e9 .

Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft S-Y, Rana I et al. ( 2019 ) . Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma . Cancers vol. 11 , ( 5 )

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K et al. ( 2019 ) . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Exposito RG, Semmianikova M, Griffiths B, Khan KH, Barber LJ, Woolston A, Spain G, von Loga K et al. ( 2019 ) . CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids . Journal of Clinical Oncology vol. 37 , ( 4_suppl ) 535 - 535 .

Exposito RG, Semmianikova M, Griffiths B, Khan KH, Barber LJ, Woolston A, Spain G, von Loga K et al. ( 2019 ) . CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids . JOURNAL OF CLINICAL ONCOLOGY . vol. 37 ,

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al. ( 2018 ) . Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing . Clinical Chemistry vol. 64 , ( 11 ) 1626 - 1635 .

Khan KH, Woolston A, Spain G, Barber L, Patil Y, Griffiths B, GonzalezExposito R, Mansukhani S et al. ( 2018 ) . Abstract 4339: Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial . Cancer Research . vol. 78 , 4339 - 4339 .

Davies MN, Barber LJ, Spain G, Lopes F, Loga KV, Griffiths B, Woolston A, Alpar D et al. ( 2017 ) . Abstract 422: Lymph node metastasis evolution drives immune evasion and targeted therapy resistance in gastro-esophageal adenocarcinomas (GEAs) . Cancer Research . vol. 77 , 422 - 422 .

Gerber T, Barber L, Huetter S, Bogen D, Davies M, Assiotis I, Berneder M, Abbasi R et al. ( 2017 ) . Visualization of intra tumor heterogeneity by simultaneous analysis of tumor and liquid biopsy samples in stage M neuroblastomas . Klinische Pädiatrie . Conference: 30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung vol. 229 , 182 - 195 .

Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M ( 2016 ) . Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine . Trends in Cancer vol. 2 , ( 1 ) 49 - 63 .

Alpar D, Barber LJ, Gerlinger M ( 2015 ) . Genetic Intratumor Heterogeneity . Epigenetic Cancer Therapy ,

Davies MN, Alpar D, Griffiths B, Barber LJ, Lipinski KA, Eltahir Z, Agoston E, Harsanyi L et al. ( 2015 ) . Intratumor heterogeneity of DNA copy number aberrations in gastric and oesophageal adenocarcinomas . Journal of Clinical Oncology . vol. 33 , 78 - 78 .

Alpar D, Barber LJ, Gerlinger M ( 2015 ) . Chapter 24 Genetic Intratumor Heterogeneity . Epigenetic Cancer Therapy , Elsevier

Barber LJ, Davies MN, Gerlinger M ( 2014 ) . Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale . Current Opinion in Genetics & Development vol. 30 , 1 - 6 .

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I et al. ( 2013 ) . The genomic landscape of oesophagogastric junctional adenocarcinoma . The Journal of Pathology vol. 231 , ( 3 ) 301 - 310 .

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T et al. ( 2013 ) . Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study . Clinical Cancer Research vol. 19 , ( 19 ) 5485 - 5493 .

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G et al. ( 2013 ) . Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer . Annals of Oncology vol. 24 , ( 5 ) 1416 - 1418 .

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN et al. ( 2013 ) . Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor . The Journal of Pathology vol. 229 , ( 3 ) 422 - 429 .

Barber LJ, Rosa JMR, Kozarewa I, Fenwick K, Assiotis I, Mitsopoulos C, Sims D, Hakas J et al. ( 2011 ) . Comprehensive Genomic Analysis of a BRCA2 Deficient Human Pancreatic Cancer . PLOS ONE vol. 6 , ( 7 )

Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A ( 2009 ) . Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 . EMBO Molecular Medicine vol. 1 , ( 6-7 ) 323 - 337 .

Meier B, Barber LJ, Liu Y, Shtessel L, Boulton SJ, Gartner A, Ahmed S ( 2009 ) . The MRT‐1 nuclease is required for DNA crosslink repair and telomerase activity in vivo in Caenorhabditis elegans . The EMBO Journal vol. 28 , ( 22 ) 3549 - 3563 .

Youds JL, Barber LJ, Boulton SJ ( 2008 ) . C. elegans: A model of Fanconi anemia and ICL repair . Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis vol. 668 , ( 1-2 ) 103 - 116 .

London TBC, Barber LJ, Mosedale G, Kelly GP, Balasubramanian S, Hickson ID, Boulton SJ, Hiom K ( 2008 ) . FANCJ Is a Structure-specific DNA Helicase Associated with the Maintenance of Genomic G/C Tracts* . Journal of Biological Chemistry vol. 283 , ( 52 ) 36132 - 36139 .

Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O'Neil NJ, Petalcorin MIR, Martin JS, Collis SJ et al. ( 2008 ) . RTEL1 Maintains Genomic Stability by Suppressing Homologous Recombination . Cell vol. 135 , ( 2 ) 261 - 271 .

Hazrati A, Ramis-Castelltort M, Sarkar S, Barber LJ, Schofield CJ, Hartley JA, McHugh PJ ( 2007 ) . Human SNM1A suppresses the DNA repair defects of yeast pso2 mutants . DNA Repair vol. 7 , ( 2 ) 230 - 238 .

Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H, Niimi A, Lehmann A et al. ( 2007 ) . Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells . Cancer Research vol. 67 , ( 18 ) 8536 - 8543 .

Ward JD, Barber LJ, Petalcorin MI, Yanowitz J, Boulton SJ ( 2007 ) . Replication blocking lesions present a unique substrate for homologous recombination . The EMBO Journal vol. 26 , ( 14 ) 3384 - 3396 .

Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ ( 2007 ) . HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability . Nature Cell Biology vol. 9 , ( 4 ) 391 - 401 .

Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, Yamada K, Ikura T, Wang X et al. ( 2007 ) . A Critical Role for the Ubiquitin-Conjugating Enzyme Ubc13 in Initiating Homologous Recombination . Molecular Cell vol. 25 , ( 5 ) 663 - 675 .

Collis S, Barber L, Martin J, Ward J, Boulton S ( 2006 ) . hCLK2 couples FANCD2 to stalled replication forks and functions in the mammalian S-phase checkpoint . Breast Cancer Research . vol. 8 ,

Barber LJ, Boulton SJ ( 2006 ) . BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg? . DNA Repair vol. 5 , ( 12 ) 1499 - 1504 .

Collis SJ, Barber LJ, Ward JD, Martin JS, Boulton SJ ( 2006 ) . C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair . DNA Repair vol. 5 , ( 11 ) 1398 - 1406 .